Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 11;12(4):ofaf143.
doi: 10.1093/ofid/ofaf143. eCollection 2025 Apr.

Efficacy and Durability of Immune Response After Receipt of Hepatitis A Vaccine in People With Human Immunodeficiency Virus

Bahaa Kazzi  1 , Amal Naji  1 , Serena Maria Dib  1 , Lana Khalil  1 , Sonia Tandon Wimalasana  1 , Diane Saint-Victor  2 , Ighovwerha Ofotokun  1 , Nadine Rouphael  1
Affiliations
Review

Efficacy and Durability of Immune Response After Receipt of Hepatitis A Vaccine in People With Human Immunodeficiency Virus

Bahaa Kazzi et al. Open Forum Infect Dis. .

Abstract

Hepatitis A virus (HAV) infection is a serious health concern among people with human immunodeficiency virus (HIV). Coinfection with HAV and HIV is linked to increased hepatitis A viral load, elevated HIV RNA, and potential disruption of HIV treatment caused by liver dysfunction. Three vaccines for the prevention of HAV are currently approved for usage in the United States: 2 monovalent inactivated vaccines (hepatitis A vaccine, inactivated [GSK] and hepatitis A vaccine, inactivated [Merck]) and 1 hepatitis A (inactivated) and hepatitis B (recombinant) vaccine (GSK). Among people with HIV (PWH), seroconversion rates and antibody titers to HAV vaccines tend to be lower and less persistent than in immunocompetent individuals, with a notable difference among PWH with a lower CD4 cell count. We highlight in this review the potential need for serologic monitoring and revaccination strategies that would optimize lifelong protection against HAV in PWH.

Keywords: HIV; hepatitis A vaccines; hepatitis A virus; immunogenicity; vaccine durability.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Emory University receives funds for N. R. to conduct research from Sanofi, Lilly, Merck, Quidel, Immorna, Vaccine Company, and Pfizer. N. R. has served on selected advisory boards for Sanofi, Seqirus, Pfizer, and Moderna and is a paid clinical trials safety consultant for ICON, CyanVac, Imunon, and EMMES. All other authors report no potential conflicts.

Similar articles

See all similar articles

References

    1. Panackel C, Thomas R, Sebastian B, Mathai SK. Recent advances in management of acute liver failure. Indian J Crit Care Med 2015; 19:27–33. - PMC - PubMed
    1. World Health Organization. Hepatitis A vaccines: WHO position paper, October 2022 . Available at: https://www.who.int/publications/i/item/who-wer9740-493-512. Accessed 15 March 2024.
    1. 2022 Viral Hepatitis Surveillance Report. Centers for Disease Control and Prevention (CDC) . 2024. Available at: https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-a/figure-1-1.html. Accessed 15 March 2024.
    1. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1–38. - PMC - PubMed
    1. Sun HY, Kung HC, Ho YC, et al. Seroprevalence of hepatitis A virus infection in persons with HIV infection in Taiwan: implications for hepatitis A vaccination. Int J Infect Dis 2009; 13:e199–205. - PubMed